SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Morgan Stanley Initiates Coverage On Akero Therapeutics with Overweight Rating, Announces Price Target of $70

Morgan Stanley analyst Matthew Harrison initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Overweight rating and announces Price Target of $70.

· 09/10/2020 06:56
Morgan Stanley analyst Matthew Harrison initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Overweight rating and announces Price Target of $70.